In the last trading session, 146.76 million shares of the BioXcel Therapeutics Inc (NASDAQ:BTAI) were traded, and its beta was 0.90. Most recently the company’s share price was $3.75, and it changed around $1.59 or 73.61% from the last close, which brings the market valuation of the company to $11.63M. BTAI currently trades at a discount to its 52-week high of $54.40, offering almost -1350.67% off that amount. The share price’s 52-week low was $1.72, which indicates that the current value has risen by an impressive 54.13% since then.
BioXcel Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.25. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended BTAI as a Hold, whereas 1 deemed it a Buy, and 1 rated it as Underweight. BioXcel Therapeutics Inc is expected to report earnings per share of -5.14 for the current quarter.
BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information
Instantly BTAI has showed a green trend with a performance of 73.61% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 6.83 on recent trading dayincreased the stock’s daily price by 45.1%. The company’s shares are currently down -37.32% year-to-date, but still up 90.36% over the last five days. On the other hand, BioXcel Therapeutics Inc (NASDAQ:BTAI) is -27.42% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $1, which translates to bulls needing to decrease their stock price by -275.0% from its current value. Analyst projections state that BTAI is forecast to be at a low of $1 and a high of $1.
BioXcel Therapeutics Inc (BTAI) estimates and forecasts
The year-over-year growth rate is expected to be 106.09%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 718.26k in revenue for the current quarter. 2 analysts expect BioXcel Therapeutics Inc to make 350k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 376k and 582k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 91.03%. Forecasts for the next quarter put sales growth at -39.86%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -35.97%. BioXcel Therapeutics Inc earnings are expected to increase by 74.52% in 2025, but the outlook is positive 50.29% per year for the next five years.
BTAI Dividends
BioXcel Therapeutics Inc’s next quarterly earnings report is expected to be released in April.
BLACKROCK INC., with 1.4276% or 0.44 million shares worth $0.56 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 55.39 shares worth $0.21 million, making up 0.11% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 18.33 shares worth around $68748.0, which represents about 0.04% of the total shares outstanding.
